

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Deucravacitinib for treating moderate to severe plaque psoriasis [ID3859]

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final Guidance

- | |
|---|
| 1. Have the potential equality issues identified during the scoping process been addressed by the committee, and, if so, how? |
|---|

In previous technology appraisals on psoriasis, it has been highlighted that the Psoriasis Area and Severity Index (PASI) can underestimate disease severity in those with black or brown skin, and that the Dermatology Life Quality Index (DLQI) has limited validity in some people, and may also miss anxiety and depression. The committee took this into account during the appraisal and included a statement on this issue in the final guidance.

- | |
|--|
| 2. Have any other potential equality issues been raised in the submissions, expert statements or academic report, and, if so, how has the committee addressed these? |
|--|

No other equality issues have been identified.
--

- | |
|--|
| 3. Have any other potential equality issues been identified by the committee, and, if so, how has the committee addressed these? |
|--|

No other equality issues have been identified.
--

4. Do the preliminary recommendations make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?
No.

5. Is there potential for the preliminary recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?
No.

6. Are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 4 or 5, or otherwise fulfil NICE's obligations to promote equality?
N/A

7. Have the committee's considerations of equality issues been described in the draft guidance, and, if so, where?
Yes. Please see section 1.5 and 1.6 of the final draft guidance and section 3.16 of the final draft guidance.

Approved by Associate Director (name):Richard Diaz.....

Date: 25 May 2023